# Table of Contents

Reviewers of Multi-Disciplinary Review and Evaluation .....

Additional Reviewers of Application .....

Glossary .....

1 Executive Summary .....
1.1. Product Introduction .....
1.2. Conclusions on the Substantial Evidence of Effectiveness .....
1.3. Benefit-Risk Assessment (BRA) .....
1.4. Patient Experience Data .....

2 Therapeutic Context .....
2.1. Analysis of Condition .....
2.2. Analysis of Current Treatment Options .....

3 Regulatory Background .....
3.1. U.S. Regulatory Actions and Marketing History .....
3.2. Summary of Presubmission/Submission Regulatory Activity .....

4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on Efficacy and Safety .....
4.1. Office of Scientific Investigations (OSI) .....
4.2. Product Quality .....
4.3. Clinical Microbiology .....
4.4. Devices and Companion Diagnostic Issues .....

5 Nonclinical Pharmacology/Toxicology .....
5.1. Executive Summary .....
5.2. Referenced NDAs, BLAs, DMFs .....
5.3. Pharmacology .....
5.4. ADME/PK .....
5.5. Toxicology .....
5.5.1. General Toxicology .....
5.5.2. Genetic Toxicology .....
5.5.3. Carcinogenicity .....
5.5.4. Reproductive and Developmental Toxicology .....

5.5.5. Other Toxicology Studies .....

6 Clinical Pharmacology .....
6.1. Executive Summary .....
6.2. Summary of Clinical Pharmacology Assessment .....
6.2.1. Pharmacology and Clinical Pharmacokinetics.....
6.2.2. General Dosing and Therapeutic Individualization .....
6.2.2.1. General Dosing .....
6.2.2.2. Therapeutic Individualization .....
6.2.2.3. Outstanding Issues .....
6.3. Comprehensive Clinical Pharmacology Review.....
6.3.1. General Pharmacology and Pharmacokinetic Characteristics .....
6.3.2. Clinical Pharmacology Questions.....

7 Sources of Clinical Data .....
7.1. Table of Clinical Studies.....

8 Statistical and Clinical Evaluation.....
8.1. Review of Relevant Individual Trials Used to Support Efficacy.....
8.1.1. [Insert Study Name].....
8.1.2. Study Results .....
8.1.3. Integrated Review of Effectiveness .....
8.1.4. Assessment of Efficacy Across Trials .....
8.1.5. Integrated Assessment of Effectiveness.....
8.2. Review of Safety .....
8.2.1. Safety Review Approach .....
8.2.2. Review of the Safety Database .....
8.2.3. Adequacy of Applicant's Clinical Safety Assessments .....
8.2.4. Safety Results.....
8.2.5. Analysis of Submission-Specific Safety Issues .....
8.2.6. Clinical Outcome Assessment (COA) Analyses Informing Safety/Tolerability .....
8.2.7. Safety Analyses by Demographic Subgroups.....
8.2.8. Specific Safety Studies/Clinical Trials .....
8.2.9. Additional Safety Explorations.....
8.2.10. Safety in the Postmarket Setting .....
8.2.11. Integrated Assessment of Safety .....

8.3. Statistical Issues .....
8.4. Conclusions and Recommendations.....
8.4.1. Approach to Substantial Evidence of Effectiveness .....
9 Advisory Committee Meeting and Other External Consultations.....
10 Pediatrics .....
11 Labeling Recommendations .....
12 Risk Evaluation and Mitigation Strategies (REMS).....
13 Postmarketing Requirements and Commitment .....
14 Division Director (DHOT) (NME ONLY).....
15 Division Director (OCP).....
16 Division Director (OB).....
17 Division Director (Clinical).....
18 Office Director (or designated signatory authority) .....
19 Appendices .....
19.1. References .....
19.2. Financial Disclosure .....
19.3. Nonclinical Pharmacology/Toxicology .....
19.4. OCP Appendices (Technical documents supporting OCP recommendations) .....
19.4.1. Population PK Analysis .....
19.4.1.1. Executive Summary .....
19.4.1.2. PPK Assessment Summary.....
19.4.1.3. PPK Review Issues .....
19.4.1.4. Reviewer's Independent Analysis.....
19.4.2. Exposure-Response Analysis.....
19.4.2.1. ER (efficacy) Executive Summary .....
19.4.2.2. ER (efficacy) Assessment Summary.....
19.4.2.3. ER (safety) Executive Summary.....
19.4.2.4. ER (safety) Assessment Summary.....
19.4.2.5. ER Review Issues.....
19.4.2.6. Reviewer's Independent Analysis.....

19.4.2.7. Overall benefit-risk evaluation based on E-R analyses.....
19.5. Additional Safety Analyses Conducted by FDA.....